瑞慈醫療(01526.HK)上半年盈轉虧至1.18億元
格隆匯8月31日丨瑞慈醫療(01526.HK)公佈,截至2022年6月30日止六個月,收入為人民幣8.756億元,較2021年同期下降12.4%;毛利為人民幣1.323億元,較2021年同期下降51.5%;公司擁有人應占虧損為人民幣1.179億元,而2021年同期的公司擁有人應占利潤為人民幣1050萬元。
報吿期間內的綜合醫院業務收入為人民幣3.161億元,較2021年同期下降4.3%,不包含截至2022年及2021年6月30日止六個月分別人民幣620萬元及人民幣980萬元的分部間收入。住院服務人次減少了2,947人次,人均住院收入上升了16.6%,住院收入下降人民幣1560萬元。同時,門診就診人次增加了127,057人次,人均門診收入下降34.3%,門診收入增加人民幣150萬元,主要是由於報吿期間內門診就診人次中新冠病毒核酸檢測人次較2021年同期大幅增加,而新冠病毒核酸檢測單價較2021年同期大幅下降。
報吿期間內的體檢業務收入為人民幣4.884億元,較2021年同期下降了20.0%。主要是報吿期內受疫情影響,遍及全國的體檢中心很多在疫情期間不能正常營業。
報吿期間內的專科醫院業務收入為人民幣7110萬元(2021年同期:人民幣5850萬元)。報吿期間我們的專科醫院分別實現門診收入及住院收入分別為人民幣3010萬元及人民幣4100萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.